Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare

BusinesswireMay 29 16:05 ET

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer.

BusinesswireMay 29 08:05 ET

Express News | Vir Biotechnology Appoints Mark Eisner, M.d., M.p.h. as Chief Medical Officer

ReutersMay 29 08:05 ET

Evaluating Vir Biotechnology: Insights From 5 Financial Analysts

Across the recent three months, 5 analysts have shared their insights on Vir Biotechnology (NASDAQ:VIR), expressing a variety of opinions spanning from bullish to bearish.The table below provides a sn

BenzingaMay 24 13:01 ET

H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $110

H.C. Wainwright analyst Patrick Trucchio maintains $Vir Biotechnology(VIR.US)$ with a buy rating, and maintains the target price at $110.According to TipRanks data, the analyst has a success rate of 2

moomoo NewsMay 24 12:32 ET

Buy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program Prospects

TipRanksMay 24 12:05 ET